美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Emera Inc.

52.04

+1.102.16%

盘后：52.640.6000+1.15%17:21 EST

成交量：20.34万

成交额：1,058.56万

市值：157.03亿

市盈率：21.11

高：52.29

开：51.17

低：51.13

收：50.94

52周最高：52.82

52周最低：43.90

股本：3.02亿

流通股本：2.99亿

量比：0.53

换手率：0.07%

股息：2.13

股息率：4.09%

每股收益(TTM):2.47

每股收益(LYR):2.47

净资产收益率：8.17%

总资产收益率：2.96%

市净率：1.79

市盈率(LYR):21.11

数据加载中...

总览公司新闻资讯公告

复宏汉霖(02696)：帕妥珠单抗生物类似药HLX11(重组抗HER2结构域II人源化单克隆抗体注射液)获欧洲药品管理局(EMA)人用医药产品委员会(CHMP)积极审评意见

百奥泰（688177）披露Gotenfia（戈利木单抗注射液）获欧洲EMA上市批准的公告，2月24日股价下跌0.68%

财报前瞻｜Emera Inc.本季度营收预计降52.39%，机构观点偏谨慎

益普生2025年业绩强劲增长，三大治疗领域稳扎稳打，并发布2026年全年指引

金丰来:减息预期金银齐扬

乐城引进帕西生长激素注射液为GHD患儿提供新选择

智通财经网

里程碑：EMA破局1型糖尿病

港股异动 | 亚盛医药-B(06855)涨超6% 耐立克®POLARIS-1研究获美国FDA和欧洲EMA批准

亚盛医药-B(06855)耐立克®一线治疗Ph+ ALL的全球注册III期临床研究获美国FDA和欧洲EMA批准

如何用100倍合约炒美股？

XRP价格预测：2.60美元阻力成为冲向3.00美元前的最后关卡

药明生物荣膺弗若斯特沙利文2025年"全球客户价值领导力奖"

EMA十月药品审评会议：赛诺菲(SNY.US)、Insmed(INSM.US)等公司新药获上市推荐

XRP价格预测：6300万美元巨鲸砸盘币安　但聪明资金已开始抄底

原研药退市连锁反应：仿制药遭“团灭”

上市公司花了1.25亿元研发的仿制药，上市申请被否！仿制对象已“翻车”：因安全性问题在欧美市场退市

每日经济新闻

马斯克给出“AI能源”解决方案：电网夜间储能、白天放电，将使美国电力产出翻倍

华尔街见闻

RWA落地实录：新能源企业的三种上链路径全解析

选年薪百万还是985学历？研究发现收入管开心，教育管健康，两者在中上水平后均趋缓

尹哥聊基因

路虎“卫士Defender运动版”纯电入门SUV路测图曝光

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/EMA/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EMA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","market":"US","secType":"STK","nameCN":"Emera Inc.","latestPrice":52.04,"timestamp":1772226000000,"preClose":50.94,"halted":0,"volume":203427,"hourTrading":{"tag":"盘后","latestPrice":52.64,"preClose":52.04,"latestTime":"17:21 EST","volume":35907,"amount":1865005.096163,"timestamp":1772230871570,"change":0.6,"changeRate":0.01153,"amplitude":0.01422},"delay":0,"changeRate":0.021594032194738936,"floatShares":298863171,"shares":301745499,"eps":2.465138,"marketStatus":"休市中","change":1.1,"latestTime":"02-27 16:00:00 EST","open":51.17,"high":52.285,"low":51.13,"amount":10585559.92032,"amplitude":0.022674,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.465138,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1772442000000},"marketStatusCode":7,"adr":0,"exchange":"NYSE","adjPreClose":50.94,"dividendRate":0.040828,"postHourTrading":{"tag":"盘后","latestPrice":52.64,"preClose":52.04,"latestTime":"17:21 EST","volume":35907,"amount":1865005.096163,"timestamp":1772230871570,"change":0.6,"changeRate":0.01153,"amplitude":0.01422},"volumeRatio":0.5252715746411913,"impliedVol":0.1097,"impliedVolPercentile":0.3025},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","floatShares":298863171,"roa":"2.96%","roe":"8.17%","lyrEps":2.465138,"volumeRatio":0.5252715746411913,"shares":301745499,"dividePrice":2.13027,"high":52.285,"amplitude":0.022674,"preClose":50.94,"low":51.13,"week52Low":43.9012,"pbRate":"1.79","psRate":"2.44","week52High":52.82,"institutionHeld":0,"latestPrice":52.04,"eps":2.465138,"divideRate":0.040935,"volume":203427,"delay":0,"ttmEps":2.465138,"open":51.17,"prevYearClose":49.24,"prevWeekClose":51.31,"prevMonthClose":49.56,"prevQuarterClose":49.24,"fiveDayClose":51.31,"twentyDayClose":50.42,"sixtyDayClose":48.73,"dividendPayoutRate":0.8394110571990734,"dividendFrequency":"Q","dividendGrowthYears":0,"fiveYearAvgDividendRate":0.04206805783252231},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EMA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-02-23","symbol":"EMA","fiscalQuarterEnding":"2025/12","expectedEps":0.43,"name":null,"time":"盘前","type":"earning","dateTimestamp":1771822800000,"reportTimeType":"pre","actualEps":0.4},{"date":"2026-01-30","symbol":"EMA","amount":0.7325,"announcedDate":"2026-01-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-01-30","defaultRemindTime":1769783400000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-02-13","payableDate":"2026-01-30","currency":"CAD","dateTimestamp":1769749200000,"payDate":"2026-02-13"},{"market":"US","date":"2025-11-07","symbol":"EMA","fiscalQuarterEnding":"2025/09","expectedEps":0.61,"name":null,"time":"盘前","type":"earning","dateTimestamp":1762491600000,"reportTimeType":"pre","actualEps":0.64},{"date":"2025-10-31","symbol":"EMA","amount":0.7325,"announcedDate":"2025-10-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-10-31","defaultRemindTime":1761917400000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-11-14","payableDate":"2025-10-31","currency":"CAD","dateTimestamp":1761883200000,"payDate":"2025-11-14"},{"market":"US","date":"2025-08-08","symbol":"EMA","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"盘前","type":"earning","dateTimestamp":1754625600000,"reportTimeType":"pre","actualEps":0.57}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EMA\",market:\"US\",,,undefined,":[{"executeDate":"2016-04-28","recordDate":"2016-05-02","paymentDate":"2016-05-16","value":0.3682105,"currency":"USD"},{"executeDate":"2016-07-20","recordDate":"2016-07-22","paymentDate":"2016-08-15","value":0.4045038,"currency":"USD"},{"executeDate":"2016-10-28","recordDate":"2016-11-01","paymentDate":"2016-11-15","value":0.3880294,"currency":"USD"},{"executeDate":"2025-08-01","recordDate":"2025-08-01","paymentDate":"2025-08-15","value":0.725,"currency":"CAD"},{"executeDate":"2025-10-31","recordDate":"2025-10-31","paymentDate":"2025-11-14","value":0.7325,"currency":"CAD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EMA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.3333,"hold":0.6,"sell":0,"strongSell":0.0667,"meanLabel":"HOLD","meanPercent":0.6,"analysts":15,"updateTime":1770267600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EMA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EMA","date":"2026-02-27","current":21.11038,"percent":0.42246,"low":16.637027,"twenty":17.349212,"median":19.603589,"eighty":20.77079,"high":21.801642,"avg":19.222723,"sd":1.599995,"marketCap":15419204876.87},"quantilePoints":[{"date":"2025-05-30","current":19.76944,"twenty":19.76944,"median":19.76944,"eighty":19.76944,"marketCap":13505496352.43},{"date":"2025-06-06","current":19.324012,"twenty":19.535669,"median":19.692043,"eighty":19.76944,"marketCap":13350532994.37},{"date":"2025-06-13","current":19.308216,"twenty":19.137627,"median":19.324012,"eighty":19.722054,"marketCap":13371262392.6},{"date":"2025-06-20","current":19.245035,"twenty":19.160372,"median":19.387193,"eighty":19.674036,"marketCap":13211518175.96},{"date":"2025-06-27","current":19.308216,"twenty":19.224185,"median":19.382455,"eighty":19.560942,"marketCap":13348226238.04},{"date":"2025-07-03","current":19.469329,"twenty":19.242508,"median":19.399829,"eighty":19.679723,"marketCap":13533023992.92},{"date":"2025-07-11","current":19.753645,"twenty":19.282944,"median":19.43142,"eighty":19.706259,"marketCap":13611556279.78},{"date":"2025-07-18","current":19.592532,"twenty":19.308216,"median":19.502499,"eighty":19.712577,"marketCap":13439260670.95},{"date":"2025-07-25","current":20.116937,"twenty":19.317694,"median":19.614646,"eighty":19.767545,"marketCap":13920070443.21},{"date":"2025-08-01","current":20.552889,"twenty":19.356234,"median":19.663612,"eighty":19.931816,"marketCap":14004388886.88},{"date":"2025-08-08","current":20.884591,"twenty":19.383402,"median":19.706259,"eighty":20.124519,"marketCap":14315223696.17},{"date":"2025-08-15","current":20.686356,"twenty":19.389088,"median":19.714157,"eighty":20.375981,"marketCap":14241020029.57},{"date":"2025-08-22","current":21.111677,"twenty":19.401724,"median":19.753645,"eighty":20.511821,"marketCap":14434555399.62},{"date":"2025-08-29","current":20.468969,"twenty":19.420679,"median":19.785235,"eighty":20.581071,"marketCap":14130173597.74},{"date":"2025-09-05","current":20.484722,"twenty":19.429525,"median":19.883167,"eighty":20.585711,"marketCap":14060435241.25},{"date":"2025-09-12","current":20.283088,"twenty":19.441529,"median":20.015847,"eighty":20.549566,"marketCap":13928376571.28},{"date":"2025-09-19","current":19.923928,"twenty":19.461747,"median":20.073945,"eighty":20.542062,"marketCap":13714455884.59},{"date":"2025-09-26","current":20.585539,"twenty":19.495865,"median":20.087756,"eighty":20.542062,"marketCap":14040465233.16},{"date":"2025-10-03","current":21.108526,"twenty":19.558414,"median":20.183278,"eighty":20.617044,"marketCap":14341364686.36},{"date":"2025-10-10","current":21.127429,"twenty":19.601378,"median":20.281209,"eighty":20.758818,"marketCap":14318469638.17},{"date":"2025-10-17","current":21.666169,"twenty":19.623491,"median":20.300416,"eighty":20.797254,"marketCap":14653790731.95},{"date":"2025-10-24","current":21.757535,"twenty":19.646868,"median":20.374454,"eighty":20.916344,"marketCap":14770054950.94},{"date":"2025-10-31","current":21.360568,"twenty":19.663296,"median":20.386244,"eighty":21.06631,"marketCap":14513331426.12},{"date":"2025-11-07","current":21.272354,"twenty":19.674036,"median":20.41226,"eighty":21.097184,"marketCap":14296037747.86},{"date":"2025-11-14","current":17.374062,"twenty":19.601378,"median":20.386244,"eighty":21.06631,"marketCap":14568586353.81},{"date":"2025-11-21","current":17.212836,"twenty":19.441529,"median":20.374454,"eighty":21.041735,"marketCap":14368588864.66},{"date":"2025-11-28","current":17.407331,"twenty":19.394143,"median":20.301992,"eighty":21.030393,"marketCap":14577653448.13},{"date":"2025-12-05","current":16.921093,"twenty":19.311375,"median":20.282148,"eighty":21.003928,"marketCap":14257439118.84},{"date":"2025-12-12","current":16.693329,"twenty":19.18059,"median":20.230664,"eighty":20.983135,"marketCap":14234564864},{"date":"2025-12-19","current":17.167393,"twenty":17.900621,"median":20.102346,"eighty":20.957301,"marketCap":14657419004.37},{"date":"2025-12-26","current":17.216186,"twenty":17.458514,"median":20.073945,"eighty":20.944699,"marketCap":14789996894.17},{"date":"2026-01-02","current":17.370269,"twenty":17.373303,"median":20.0392,"eighty":20.932097,"marketCap":14871263471.89},{"date":"2026-01-09","current":17.43447,"twenty":17.368214,"median":19.923928,"eighty":20.903742,"marketCap":14773589152.84},{"date":"2026-01-16","current":17.439606,"twenty":17.353836,"median":19.83736,"eighty":20.887161,"marketCap":14748903694.51},{"date":"2026-01-23","current":17.57828,"twenty":17.358457,"median":19.76786,"eighty":20.862056,"marketCap":14967122519.73},{"date":"2026-01-30","current":17.452446,"twenty":17.36616,"median":19.731531,"eighty":20.822459,"marketCap":15149245081.41},{"date":"2026-02-06","current":17.639913,"twenty":17.358457,"median":19.706259,"eighty":20.792844,"marketCap":15150466223.22},{"date":"2026-02-13","current":17.632209,"twenty":17.329694,"median":19.687304,"eighty":20.780241,"marketCap":15197950382.19},{"date":"2026-02-20","current":18.01228,"twenty":17.336884,"median":19.662032,"eighty":20.776461,"marketCap":15461241242.05},{"date":"2026-02-27","current":19.370854,"twenty":17.349212,"median":19.603589,"eighty":20.77079,"marketCap":15419204876.87}],"updateTime":1772284820786},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EMA\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2614085473","title":"复宏汉霖(02696)：帕妥珠单抗生物类似药HLX11(重组抗HER2结构域II人源化单克隆抗体注射液)获欧洲药品管理局(EMA)人用医药产品委员会(CHMP)积极审评意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2614085473","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614085473?lang=zh_cn&edition=fundamental","pubTime":"2026-02-27 22:27","pubTimestamp":1772202451,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，HLX11获EMA人用医药产品委员会积极审评意见，推荐批准HLX11的上市许可申请。倘若获得EC批准，HLX11的集中上市许可将在所有欧盟成员国及欧洲经济区国家冰岛、列支敦士登和挪威生效。HLX11是本公司自主研发的帕妥珠单抗生物类似药。2024年12月，HLX11的上市注册申请获国家药品监督管理局受理。2025年3月，HLX11的上市许可申请获欧洲药品管理局受理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408509.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4087","BK1574","HK0000320264.USD","BK4081","HK0000320223.HKD","CHMP","159938","EMA","HK0000306685.HKD","BK1515","BK1161","HK0000165453.HKD","HK0000306701.USD","02696","09939"],"gpt_icon":0},{"id":"2613797244","title":"百奥泰（688177）披露Gotenfia（戈利木单抗注射液）获欧洲EMA上市批准的公告，2月24日股价下跌0.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613797244","media":"中金财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613797244?lang=zh_cn&edition=fundamental","pubTime":"2026-02-24 18:41","pubTimestamp":1771929669,"startTime":"0","endTime":"0","summary":"百奥泰生物制药股份有限公司近日披露公告，公司收到欧洲药品管理局通知，其开发的戈利木单抗注射液已获EMA上市批准。BAT2506是依据NMPA、FDA和EMA指导原则开发的生物类似药，目前上市申请已获NMPA、FDA及巴西国家卫生监督局受理。该批准有望对公司长期经营业绩产生积极影响，但未来可能面临激烈市场竞争。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260224/32024193.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","EMA","BK4081","688177"],"gpt_icon":0},{"id":"1189502436","title":"财报前瞻｜Emera Inc.本季度营收预计降52.39%，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1189502436","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189502436?lang=zh_cn&edition=fundamental","pubTime":"2026-02-16 10:14","pubTimestamp":1771208088,"startTime":"0","endTime":"0","summary":"Emera Inc.将于2026年02月23日美股盘前发布最新季度财报，市场关注营收与每股收益的同比下滑幅度及业务结构变化。市场一致预期显示，本季度Emera Inc.营收预计为9.66亿美元，同比下降52.39%；调整后每股收益预计为0.56美元，同比下降27.14%；息税前利润预计为2.11亿美元，同比下降72.86%。上季度Emera Inc.营收21.06亿美元，同比增长16.87%；毛利率44.06%；归属母公司净利润2.47亿美元，净利率11.73%，净利润环比增长60.39%；调整后每股收益0.88美元，同比增长8.64%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜Emera Inc.本季度营收预计降52.39%，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA"],"gpt_icon":0},{"id":"2611077151","title":"益普生2025年业绩强劲增长，三大治疗领域稳扎稳打，并发布2026年全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2611077151","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611077151?lang=zh_cn&edition=fundamental","pubTime":"2026-02-13 19:49","pubTimestamp":1770983340,"startTime":"0","endTime":"0","summary":"\" 2026年全年指引及中期展望 益普生为2026财年制定了以下财务指引：  以固定汇率计算，总销售额增长超过13.0%。研发管线进展 2025年，益普生在不同产品组合实现多项重要的监管和临床里程碑，反映了三个治疗领域的研发管线持续推进。2025年9月，益普生公布了IPN10200在医美领域LANTIC Ⅱ期临床的积极数据，显示该产品具有差异化的长效临床特征。外部创新 2025年12月，益普生通过收购ImCheck Therapeutics进一步扩展了肿瘤免疫治疗产品组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4887760_ZH87760_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4081","EMA","IPSEF","CAGR","IPN","BOLD","BK4159","BK4007","BK4139"],"gpt_icon":0},{"id":"2592716325","title":"金丰来:减息预期 金银齐扬","url":"https://stock-news.laohu8.com/highlight/detail?id=2592716325","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592716325?lang=zh_cn&edition=fundamental","pubTime":"2025-12-19 18:32","pubTimestamp":1766140320,"startTime":"0","endTime":"0","summary":"贵金属市场在周三普遍大幅上涨，金价盘中一度飙升约1%，白银更是上涨近4%，首次突破66美元关口，并创下66.89美元的历史新高。金丰来认为，此轮上涨主要受到美国疲软就业数据的影响，引发市场对美联储2026年再次减息的预期。市场目前关注美国CPI和PCE通胀数据，以寻求更多关于美联储政策路径的线索。金丰来认为，加密货币市场波动性大、机会丰富，长期仍有潜力。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/future/roll/2025-12-19/doc-inhciuai2224548.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4150","EMA","RSI","MGCmain","SImain","BK4081"],"gpt_icon":0},{"id":"2589334696","title":"乐城引进帕西生长激素注射液 为GHD患儿提供新选择","url":"https://stock-news.laohu8.com/highlight/detail?id=2589334696","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589334696?lang=zh_cn&edition=fundamental","pubTime":"2025-12-08 18:40","pubTimestamp":1765190402,"startTime":"0","endTime":"0","summary":"今年1月，诺和诺德长效生长激素——帕西生长激素注射液作为临床急需药物被引入乐城博鳌未来医院(海南省妇女儿童医学中心乐城分院)，并于5月正式投入临床。目前，该药已惠及20余例年龄在4.5至14.5岁之间的生长激素缺乏症(GHD)患儿，为我国GHD患儿提供了新的治疗选择。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20251208/20251208183409_27282.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251208/20251208183409_27282.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378903.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4208","IE00BMG7P694.USD","EMA","IE00BMG7P819.SGD","IE00BMG7P587.USD","IE00BD4GTV84.USD","BK4585","IE00BD4GTT62.SGD","IE00BMG7P926.USD","LU2346227817.USD","IE00BD4GTW91.USD","BK4588","BK4081","PEG"],"gpt_icon":0},{"id":"2589933712","title":"里程碑：EMA破局1型糖尿病","url":"https://stock-news.laohu8.com/highlight/detail?id=2589933712","media":"药事纵横","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589933712?lang=zh_cn&edition=fundamental","pubTime":"2025-12-08 07:02","pubTimestamp":1765148528,"startTime":"0","endTime":"0","summary":"2025年11月14日，EMA发布了一项具有里程碑意义的积极意见：推荐批准Teizelid在欧盟上市，用于延迟8岁及以上2期1型糖尿病患者进展至3期1型糖尿病。据统计，欧盟范围内约有220万人患有1型糖尿病，其中许多是儿童。2019年10月17日，teplizumab因其在“高危人群中延迟或预防临床1型糖尿病”方面的潜力获得PRIME资格。该研究共纳入76名2期1型糖尿病患者，其中44人接受teplizumab治疗，32人接受安慰剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208072113a439f849&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208072113a439f849&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EMA","BK4081"],"gpt_icon":0},{"id":"2589519008","title":"港股异动 | 亚盛医药-B(06855)涨超6% 耐立克®POLARIS-1研究获美国FDA和欧洲EMA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2589519008","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589519008?lang=zh_cn&edition=fundamental","pubTime":"2025-12-05 09:33","pubTimestamp":1764898401,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，亚盛医药-B涨超6%，截至发稿，涨5.67%，报64.2港元，成交额1993.31万港元。消息面上，12月5日，亚盛医药-B发布公告，公司原创1类新药奥雷巴替尼联合化疗治疗新诊断费城染色体阳性(Ph+)急性淋巴细胞白血病患者的全球注册III期临床研究获美国食品药品监督管理局和欧洲药品管理局同意开展。作为耐立克在欧美监管机构获批的第二个全球注册III期研究，POLARIS-1研究在多国家多中心同步入组，将加速耐立克全球特别是欧美市场的上市进程。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377993.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","BK4081","BK1161","BK4139","EMA","06855","BK1574"],"gpt_icon":0},{"id":"2589985521","title":"亚盛医药-B(06855)耐立克®一线治疗Ph+ ALL的全球注册III期临床研究获美国FDA和欧洲EMA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2589985521","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589985521?lang=zh_cn&edition=fundamental","pubTime":"2025-12-05 08:03","pubTimestamp":1764893004,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，公司原创1类新药奥雷巴替尼联合化疗治疗新诊断费城染色体阳性(Ph+)急性淋巴细胞白血病患者的全球注册III期临床研究获美国食品药品监督管理局和欧洲药品管理局同意开展。同时，耐立克在Ph+ ALL领域深度布局，针对Ph+ ALL领域的治疗已获《CSCO恶性血液病诊疗指南》连续推荐，并获CDE突破性疗法认定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377959.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1571399168.USD","LU2355687059.USD","III","BK4134","ALL","LU0985320562.USD","BK4533","BK1574","EMA","BK4585","BK4107","06855","BK4139","BK4081","BK4588","LU1699723380.USD","AAPG","BK1161"],"gpt_icon":0},{"id":"2586276970","title":"如何用100倍合约炒美股？","url":"https://stock-news.laohu8.com/highlight/detail?id=2586276970","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586276970?lang=zh_cn&edition=fundamental","pubTime":"2025-11-28 08:34","pubTimestamp":1764290040,"startTime":"0","endTime":"0","summary":"永续合约，正以一种不可阻挡的姿态与美股市场结合。trade.xyz trade.xyz 是首个基于 Hyperliquid HIP-3 协议部署的永续 DEX，也是 HIP-3 上最大的永续 DEX，于 2025 年 10 月上线。相关阅读：《10 天 20 亿美金交易量，Hyperliquid 的又一个爆款》。主流科技股比如苹果、亚马逊、Meta、微软、英伟达和特斯拉等支持高达 100 倍杠杆。指数产品并不直接依赖美股的现货，而是使用 CME 的 NQ 期货——这类期货每天有 23 小时在交易，因此价格来源更连续。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info/news/60366","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_zh_highlight","symbols":["BK4200","SIG","EMA","NQmain","BK4081"],"gpt_icon":0},{"id":"2580257426","title":"XRP价格预测：2.60美元阻力成为冲向3.00美元前的最后关卡","url":"https://stock-news.laohu8.com/highlight/detail?id=2580257426","media":"cryptonews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580257426?lang=zh_cn&edition=fundamental","pubTime":"2025-11-03 12:40","pubTimestamp":1762144818,"startTime":"0","endTime":"0","summary":"\n                                            \nXRP价格目前在约2.55美元区间交易，日涨幅约1.7%，交易量已突破21.6亿美元。尽管出现反弹，XRP仍被压制在约2.60美元的强劲阻力位下方。技术指标显示，该价位附近可能即将出现关键性突破。\n\n\n\n凭借1530亿美元的市值，XRP依然稳居全球第四大加密货币，但随着市场结构逐渐收紧、动能趋于集中，交易者正密切关注关键价位的变化。\n\n\n\n技术面分析：下降三角形压力\n\n\n\nXRP的日线图显示出一个下降三角形形态，这通常被视为在支撑失守时的看跌延续信号。从3.15美元起的下降趋势线持续压制价格上行动能，而约2.54美元的支撑位则成为多头的最后防线。\n\n\n\n\n\n\n\n尽管近期价格有所回升，XRP仍低于其50日指数移动平均线（EMA），显示卖方在短期市场情绪中仍占主导地位。相对强弱指数（RSI）徘徊在48附近，表明动能中性，但出现看跌背离迹象。价格趋于稳定，而RSI未能创出新高，这种背离通常预示买盘力度减弱及趋势可能衰竭。\n\n\n\n近期的蜡烛图形态以十字星与纺锤线为主，反映市场犹豫情绪。交易者将关注是否...                                        ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://cryptonews.com/cn/news/xrp-price-prediction-2-60-resistance-the-last-hurdle-before-a-potential-move-to-3-00/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"cryptonews_cn_highlight","symbols":["BK4594","SVM","83042","BK4150","BK4585","09008","03008","BK4601","BTC.USD.CC","BK1611","BTC.USD.HKCC","03042","03439","SOL.USD.HKCC","09439","BK4081","MBTmain","EMA","BK4588","09042","RSI","BK4210"],"gpt_icon":1},{"id":"2577869263","title":"药明生物荣膺弗若斯特沙利文2025年\"全球客户价值领导力奖\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2577869263","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577869263?lang=zh_cn&edition=fundamental","pubTime":"2025-10-20 17:30","pubTimestamp":1760952600,"startTime":"0","endTime":"0","summary":"上海2025年10月20日 /美通社/ -- 全球领先的合同研究、开发和生产服务公司药明生物宣布，公司荣获弗若斯特沙利文颁发的2025年生物药CRDMO行业 \"全球客户价值领导力奖\"。该奖项表彰了药明生物通过技术创新、卓越运营及对客户需求的前瞻洞察，持续为客户创造卓越价值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4801893_ZH01893_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0417516738.SGD","LU0823426308.USD","02269","LU0516422952.EUR","LU0051755006.USD","WXXWY","LU0052750758.USD","BK1610","LU0588546209.SGD","SG9999002463.SGD","LU0320764599.SGD","LU0359201612.USD","LU0819121731.USD","BK1521","LU0307460666.USD","LU0516423174.USD","LU0516422366.SGD","BK1576","BK4121","IE00B0JY6N72.USD","LU0348825331.USD","LU0856984785.SGD","LU0456827905.SGD","LU0140636845.USD","LU1242518857.USD","LU1720050803.USD","LU1688375341.USD","LU0359202008.SGD","LU1794554557.SGD","LU0181495838.USD","LU3063872942.SGD","BK1589","LU0417516902.SGD","LU0979878070.USD","LU2039709279.SGD","LU0708995583.HKD","EMA","LU0326950275.SGD","LU1880383366.USD","LU0516422440.USD","BK4081","LU0823426480.USD","LU0039217434.USD","LU0043850808.USD","LU0327786744.USD","LU1242518931.SGD","BK1141","LU0456846285.SGD","LU0348735423.USD","LU0516423091.SGD"],"gpt_icon":0},{"id":"2576055837","title":"EMA十月药品审评会议：赛诺菲(SNY.US)、Insmed(INSM.US)等公司新药获上市推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2576055837","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576055837?lang=zh_cn&edition=fundamental","pubTime":"2025-10-17 21:29","pubTimestamp":1760707780,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，在本周召开的会议上，欧洲药品管理局的专家小组对赛诺菲与Insmed的两款新药做出了推荐在该地区上市的积极意见。除了推荐新药获批外，该委员会还否决了赛诺菲的一款新药，并推荐了8项新的药品适应症扩展申请。赛诺菲表示，这一决定基于该公司关键的LUNA 3期临床试验。该公司表示，CHMP的这一决定令人失望，并将寻求对该决定进行重新审查。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1356643.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4081","BK4007","INSM","LU0889565916.HKD","BK4585","EMA","IE00BFXG1179.USD","BK4139","LU0320765992.SGD","LU0053671581.USD","BK4588","SNY","LU0109394709.USD"],"gpt_icon":0},{"id":"2575710341","title":"XRP价格预测：6300万美元巨鲸砸盘币安　但聪明资金已开始抄底","url":"https://stock-news.laohu8.com/highlight/detail?id=2575710341","media":"cryptonews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575710341?lang=zh_cn&edition=fundamental","pubTime":"2025-10-16 17:43","pubTimestamp":1760607816,"startTime":"0","endTime":"0","summary":"\n                                            \n一笔高达 6300万美元的XRP巨鲸转账 在周五暴跌期间流入币安，引发市场热议，但分析师依旧维持看涨预期，因为聪明钱已经开始 低位吸筹。\n\n\n\n买盘在 2美元关口 附近强势介入，显示出即便在市场震荡中，仍有资金对XRP保持高信心。\n\n\n\n过去24小时内，XRP 上涨了1.6%至2.50美元，交易量依旧活跃，占其流通市值的约4%，这暗示市场动能或正在重新回归多头阵营。\n\n\n\n与此同时，ETF资金面保持稳健。新上线的 REX-Osprey XRP ETF（XRPR） 依然管理着超过 9000万美元 的XRP资产，与上周几乎持平。\n\n\n\n整体来看，那些钻石手 的XRP持有者明显利用上周的回调...                                        ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://cryptonews.com/cn/news/xrp-price-prediction-63m-whale-dump-hits-binance-but-smart-money-is-already-buying-the-dip/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"cryptonews_cn_highlight","symbols":["EMA","XRPR","RSI","BK4150","BK4081"],"gpt_icon":0},{"id":"2575290118","title":"原研药退市连锁反应：仿制药遭“团灭”","url":"https://stock-news.laohu8.com/highlight/detail?id=2575290118","media":"新浪医药","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575290118?lang=zh_cn&edition=fundamental","pubTime":"2025-10-14 19:29","pubTimestamp":1760441340,"startTime":"0","endTime":"0","summary":"10月11日，NMPA下发了43条不带药品批号的“通知件”，其中包括复旦张江的奥贝胆酸片。复旦张江奥贝胆酸片的进口原研药因安全性问题在海外“翻车”，遭欧美市场退市，是此次监管机构不予批准的主要原因。国产仿制药被波及随着原研药安全性风险的暴露以及在欧美市场接连退市，其在国内的仿制前景也面临极大的不确定性。截至目前，国内尚无奥贝胆酸上市。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2025-10-14/doc-inftwhpf1932544.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","FXR","PBC","BK4585","CMA","BK4207","BK4081","BK4211","EMA","BK4589"],"gpt_icon":0},{"id":"2575025050","title":"上市公司花了1.25亿元研发的仿制药，上市申请被否！仿制对象已“翻车”：因安全性问题在欧美市场退市","url":"https://stock-news.laohu8.com/highlight/detail?id=2575025050","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575025050?lang=zh_cn&edition=fundamental","pubTime":"2025-10-14 12:55","pubTimestamp":1760417700,"startTime":"0","endTime":"0","summary":"仿制对象已“翻车”：因安全性问题在欧美市场退市，所有相关临床试验被暂停。　　10月13上市公司花了1.25亿元研发的仿制药，上市申请被否！　　复旦张江奥贝胆酸片的进口原研药因安全性问题在海外“翻车”，遭欧美市场退市，是此次监管机构不予批准的主要原因。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2025-10-14/doc-inftvrrq4485805.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-10-14/doc-inftvrrq4485805.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4201","PBC","BK0239","688505","BK4081","EC","EMA","FXR"],"gpt_icon":0},{"id":"2574545435","title":"马斯克给出“AI能源”解决方案：电网夜间储能、白天放电，将使美国电力产出翻倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2574545435","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574545435?lang=zh_cn&edition=fundamental","pubTime":"2025-10-11 14:29","pubTimestamp":1760164181,"startTime":"0","endTime":"0","summary":"马斯克近日提出通过大规模部署工业级电池储能系统，可将美国电网有效发电能力提升一倍，为解决AI能源危机提供清晰路径。","market":"us","thumbnail":"https://static.tigerbbs.com/ee293fe5629ee0ea9f80cfafff4b2fa4","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ee293fe5629ee0ea9f80cfafff4b2fa4"],"rights":{"source":"wallstreetcn_api","url":"https://wallstreetcn.com/articles/3756998","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3756998","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_api","symbols":["DUK","OKLO","CMS","D","SO","EMA","VIA","ED","WEC"],"gpt_icon":1},{"id":"2574183488","title":"RWA落地实录：新能源企业的三种上链路径全解析","url":"https://stock-news.laohu8.com/highlight/detail?id=2574183488","media":"BitPush","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574183488?lang=zh_cn&edition=fundamental","pubTime":"2025-10-09 10:06","pubTimestamp":1759975594,"startTime":"0","endTime":"0","summary":"RWA并非全新的概念，但近期再次受到广泛关注。真正有价值的 RWA，并不只是把现有金融产品搬到链上，而是将区块链能力深度嵌入传统行业的真实业务，实现数据可信、流程自动与融资创新的融合。本文以新能源行业为例，拆解传统企业实施 RWA 的三种路径，展示区块链如何提升传统业务的数据可信度、结算效率和融资空间，帮助读者理解其差异、选择适合方案并预判其中风险。","market":"us","thumbnail":"https://images.bitpush.news/2025/10/special_cn-20251009-175997565171312274.png:微信图片_20251009100712_8_3-200x140.png","type":0,"news_type":0,"thumbnails":["https://images.bitpush.news/2025/10/special_cn-20251009-175997565171312274.png:微信图片_20251009100712_8_3-200x140.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bitpush.news//articles/7577039","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"bit_push_news","symbols":["BK4588","LU1596574779.USD","REC","SG9999001440.SGD","BK4081","LU1721427968.SGD","LU0170899867.USD","LU1620156213.USD","BK4585","LU1543694498.USD","LU1165135440.EUR","LU1620156130.USD","LU2413665964.HKD","BK4086","LU2413666004.HKD","EMA"],"gpt_icon":0},{"id":"2572522557","title":"选年薪百万还是985学历？研究发现收入管开心，教育管健康，两者在中上水平后均趋缓","url":"https://stock-news.laohu8.com/highlight/detail?id=2572522557","media":"尹哥聊基因","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572522557?lang=zh_cn&edition=fundamental","pubTime":"2025-10-03 08:02","pubTimestamp":1759449720,"startTime":"0","endTime":"0","summary":"最近社交媒体上有一个热门话题：“给你一百万，或者一个985名校的学历，你会选哪个？”04社区层面影响接着，研究者将分析扩展至社区层面，考察一个地区的平均收入和教育水平是否影响其中个体的健康与幸福。研究发现，钱和学历的“边际效益”会递减。△ 主观收入、教育和结果衡量之间的非线性关系06小结综上，这项研究告诉我们：收入管“开心”，教育管“健康”，换句话说，钱能买来今天的笑容，但","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-10-03/doc-infsqhux7979650.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["EMA","SES","BK4603","BK4096","BK4081"],"gpt_icon":0},{"id":"2570857812","title":"路虎“卫士Defender运动版”纯电入门SUV路测图曝光","url":"https://stock-news.laohu8.com/highlight/detail?id=2570857812","media":"IT之家","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570857812?lang=zh_cn&edition=fundamental","pubTime":"2025-09-27 11:00","pubTimestamp":1758942013,"startTime":"0","endTime":"0","summary":"IT之家 9 月 27 日消息，汽车媒体 CarScoops 今天发布博文，分享了一组在欧洲抓拍到的照片，展示了捷豹路虎正在测试的“卫士运动版”入门 SUV，预计于 2027 年面世。该 SUV 基于电动模块化架构平台，采用 800 伏充电架构，是捷豹路虎电动化蓝图中的关键产品。该媒体预估路虎增强户外探险场景，将提供环绕式玻璃区域、悬浮式车顶及双色涂装选项，并可搭配多种定制化配件。该媒体推测为延续路虎的越野基因，车辆将搭载双电机组合，具备先进全轮驱动能力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8mzC8GZZNzz","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["EMA","BK4081"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":28,"code":"91000000","status":"200"}]}}